1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML
By Steve Bryson PhD on Oct 07, 2021 One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare…
B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS
New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against…
Stuart Schlossman
MS Therapies That Deplete B-cells Appear to Work Against COVID Immunity
MAY 14, 2021 BY STEVE BRYSON PHD Click HERE to Subscribe for the MS Beacon eNewsletter! B-cell-depleting…
Stuart Schlossman
Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients
Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive of multiple sclerosis (MS),…
Stuart Schlossman
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Abstract Background: There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory…
Stuart Schlossman
Black MS Patients See More Rapid B-Cell Repopulation
May have implications for timing of lab draws and anti-CD20 dosing, researchers say by Ed Susman, Contributing Writer, MedPage Today April 20, 2021…
Stuart Schlossman
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
April 16, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no…
Stuart Schlossman
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
Click HERE to Subscribe for the MS Beacon Newsletter · Approval based on data from the randomized, double-blind ENSEMBLE PLUS…
Stuart Schlossman
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
* 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease…
Stuart Schlossman
Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS
Jul 02, 2020 — Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC)…
Stuart Schlossman
